

    BOXED WARNING: WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS

    WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS  

    *  Fluoroquinolones, including LEVAQUIN(r), have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5.1)], including:Tendinitis and tendon rupture [see Warnings and Precautions (5.2)]Peripheral neuropathy [see Warnings and Precautions (5.3)]Central nervous system effects [see Warnings and Precautions (5.4)]Discontinue LEVAQUIN immediately and avoid the use of fluoroquinolones, including LEVAQUIN, in patients who experience any of these serious adverse reactions [see Warnings and Precautions (5.1)] 
 *  Fluoroquinolones, including LEVAQUIN(r), may exacerbate muscle weakness in patients with myasthenia gravis. Avoid LEVAQUIN(r) in patients with a known history of myasthenia gravis [see Warnings and Precautions (5.5)]. 
 *  Because fluoroquinolones, including LEVAQUIN, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)], reserve LEVAQUIN for use in patients who have no alternative treatment options for the following indications:Uncomplicated urinary tract infection [see Indications and Usage (1.12)]Acute bacterial exacerbation of chronic bronchitis [see Indications and Usage (1.13)]Acute bacterial sinusitis [see Indications and Usage (1.14)]. 
      EXCERPT:     WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS  
 

   See full prescribing information for complete boxed warning.  

   Fluoroquinolones, including LEVAQUIN  (r)  , have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together (  5.1  ), including:  

 *  Tendinitis and tendon rupture (5.2) 
 *  Peripheral neuropathy (5.3) 
 *  Central nervous system effects (5.4) 
      Discontinue LEVAQUIN immediately and avoid the use of fluoroquinolones, including LEVAQUIN, in patients who experience any of these serious adverse reactions (  5.1  )  
 

   Fluoroquinolones, including LEVAQUIN  (r)  , may exacerbate muscle weakness in patients with myasthenia gravis. Avoid LEVAQUIN  (r)   in patients with a known history of myasthenia gravis   [see   Warnings and Precautions (5.5)  ]  .  

   Because fluoroquinolones, including LEVAQUIN, have been associated with serious adverse reactions (5.1-5.14), reserve LEVAQUIN for use in patients who have no alternative treatment options for the following indications:  

 *  Uncomplicated urinary tract infection (1.12) 
 *  Acute bacterial exacerbation of chronic bronchitis (1.13) 
 *  Acute bacterial sinusitis (1.14) 
    

